Chinese inhibitor drug candidate becomes first to enter phase
Time:2024-05-21 16:44:23 Source:entertainmentViews(143)
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Previous:Revealed: Brit tourist, 19, subjected to sex attack in Majorca 'was gang
Next:Biden says Brown v. Board of Education ruling was about more than education
You may also like
- What's next for Iran after death of its president in crash?
- China compiles inventory of 914,000 patents: CNIPA
- China Coast Guard issues warnings to trespassing Philippine vessels
- China develops first 100 kg vehicle
- Elon Musk gets approval from FDA to implant his Neuralink brain chip into a second patient
- China compiles inventory of 914,000 patents: CNIPA
- Luzardo leads Marlins to third consecutive shutout win, 8
- China discloses tasks of Shenzhou
- Shooting injures 2 at Missouri high school graduation ceremony